R Češka
About
In The Last Decade
R Češka
166 papers receiving 4.6k citations
Hit Papers
Peers
Comparison fields: 5 of 121
- Surgery 3.4k
- Endocrinology, Diabetes and Metabolism 1.3k
- Cardiology and Cardiovascular Medicine 1.1k
- Economics and Econometrics 1000
- Cancer Research 742
Countries citing papers authored by R Češka
This map shows the geographic impact of R Češka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Češka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Češka more than expected).
Fields of papers citing papers by R Češka
This network shows the impact of papers produced by R Češka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Češka. The network helps show where R Češka may publish in the future.
Co-authorship network of co-authors of R Češka
This figure shows the co-authorship network connecting the top 25 collaborators of R Češka. A scholar is included among the top collaborators of R Češka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R Češka. R Češka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 5 | |
| 2 | 1 | |
| 3 | Společné stanovisko odborných společností k předepisování inhibitorů PCSK9 | 0 |
| 4 | 1 | |
| 5 | [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment]. | 2 |
| 6 | [Familial hypercholesterolemia in the Czech Republic in 2016]. | 1 |
| 7 | Abstract 15100: Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial | 3 |
| 8 | 20 | |
| 9 | [PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement]. | 1 |
| 10 | ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia breakdown → | 418 |
| 11 | The role of a center for tobacco-dependent in cardiovascular prevention. A retrospective study. | 3 |
| 12 | 39 | |
| 13 | Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk. | 16 |
| 14 | 14 | |
| 15 | 4 | |
| 16 | 3 | |
| 17 | 28 | |
| 18 | 23 | |
| 19 | 5 | |
| 20 | 21 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.